Thus, this study identifies and validates PARP1 as a candidate drug target in RAD54B-deficient CRC cells, and identifies BMN673 and Olaparib as novel candidate chemotherapeutic agents in a RAD54B-specific CRC context. Here, RAD54B is linked to colorectal carcinoma.